Next-generation diagnostics is significantly transforming basic cell, molecular biology, and disease research, aiding in developing new gene and cancer therapies.
Germany, the U.S., the U.K., and France, are introducing national policies to increase genomics research and diagnostic capacity. Governments worldwide are forging cancer screening programs to determine cancer indications, including lung, breast, colon, prostate, melanoma, thyroid, bladder, and others.
Medical professionals prefer DNA microarrays, molecular diagnostics, next-generation sequencing, and protein microarrays for cancer diagnosis as they allow for high-throughput, precise, and affordable DNA or RNA sequencing.
Additionally, clinical research organizations, including Precision for Medicine, are announcing the Next Generation Sequencing (NGS) initiative to allow researchers and manufacturers to develop patient-specific diagnostics for improved clinical outcomes.
Companies are raising funds to advance diagnostic technologies and improve treatment efficiency. In November 2022, Haystack Oncology raised USD 56 million in Series A funding led by Catalio Capital Management for developing and commercializing its personalized cancer diagnostic test that can detect one mutant molecule in a million DNA molecules.
Ongoing investments for increasing cancer diagnostic research, initiatives for cancer treatment, and advances in next-generation diagnostics are set to evolve the next big thing in oncology.